Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 23 articles: HTML format

Single Articles

April 2023
1. CAI C, He H, Duan X, Wu W, et al
   [Corrigendum] miR‑195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
   Oncol Rep. 2023;49:70.
   PubMed     Abstract available
   
   
   March 2023
2. KOU B, Liu W, Zhao W, Duan P, et al
   [Corrigendum] Thymoquinone inhibits epithelial‑mesenchymal transition in prostate cancer cells by negatively regulating the TGF‑beta/Smad2/3 signaling pathway.
   Oncol Rep. 2023;49:54.
   PubMed     Abstract available
   
   
   
3. XIE H, Zhao J, Wan J, Zhao J, et al
   [Corrigendum] Long non‑coding RNA AC245100.4 promotes prostate cancer tumorigenesis via the microRNA‑145‑5p/RBBP5 axis.
   Oncol Rep. 2023;49:62.
   PubMed     Abstract available
   
   
   January 2023
4. WANG H, Zhang M, Lu W, Yuan C, et al
   Prostate cancer cell‑derived spondin 2 boosts osteogenic factor levels in osteoblasts via the PI3K/AKT/mTOR pathway.
   Oncol Rep. 2023;49:23.
   PubMed     Abstract available
   
   
   December 2022
5. SUN W, Li L, Du Z, Quan Z, et al
   [Corrigendum] Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   
6. PU J, Li T, Liu N, Luo C, et al
   [Corrigendum] PLCepsilon knockdown enhances the radiosensitivity of castrationresistant prostate cancer via the AR/PARP1/DNAPKcs axis.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   November 2022
7. CHEN J, Xu D, Wang T, Yang Z, et al
   HMGB1 promotes the development of castrationresistant prostate cancer by regulating androgen receptor activation.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   October 2022
8. YIN B, Liu Z, Wang Y, Wang X, et al
   [Corrigendum] RON and cMet facilitate metastasis through the ERK signaling pathway in prostate cancer cells.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   August 2022
9. MENDEZ-CLEMENTE A, Bravo-Cuellar A, Gonzalez-Ochoa S, Santiago-Mercado M, et al
   Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL6/IL6R/STAT3 axis.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   July 2022
10. LIN J, Chen Z, Li Z, Nong D, et al
    [Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    May 2022
11. XU T, Liu Y, Schulga A, Konovalova E, et al
    Epithelial cell adhesion moleculetargeting designed ankyrin repeat proteintoxin fusion Ec1LoPE exhibits potent cytotoxic action in prostate cancer cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    
12. CHEN F, Lu Z, Deng J, Han X, et al
    [Corrigendum] SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
13. GU P, Zhang M, Zhu J, He X, et al
    Suppression of CDCA3 inhibits prostate cancer progression via NFkappaB/cyclin D1 signaling inactivation and p21 accumulation.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
14. LIU J, Zhang Y, Li S, Sun F, et al
    Androgen deprivationinduced OPHN1 amplification promotes castrationresistant prostate cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    December 2021
15. CHEN B, Bai G, Ma X, Tan L, et al
    MicroRNA1955p is associated with cell proliferation, migration and invasion in prostate cancer and targets MIB1.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
16. ZHAO J, Li Q, Feng B, Wei D, et al
    MicroRNA149 inhibits cancer cell malignant phenotype by regulating Akt1 in C42 CRPC cell line.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    November 2021
17. SHENG W, Xu W, Ding J, Li L, et al
    Curcumol inhibits the malignant progression of prostate cancer and regulates the PDK1/AKT/mTOR pathway by targeting miR9.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    September 2021
18. DU W, Li D, Xie J, Tang P, et al
    miR3673p downregulates Rab23 expression and inhibits Hedgehog signaling resulting in the inhibition of the proliferation, migration, and invasion of prostate cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
19. LIN J, Chen Z, Li Z, Nong D, et al
    Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    August 2021
20. TORRES MJ, Lopez-Moncada F, Herrera D, Indo S, et al
    Endothelin-1 induces changes in the expression levels of steroidogenic enzymes and increases androgen receptor and testosterone production in the PC3 prostate cancer cell line.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
21. LI JM, Lee S, Zafar R, Shin E, et al
    Sodium bicarbonate transporter NBCe1 regulates proliferation and viability of human prostate cancer cells LNCaP and PC3.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    March 2021
22. ZHU J, Qin P, Cao C, Dai G, et al
    Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Oncol Rep. 2021;45:963-974.
    PubMed     Abstract available
    
    
    
23. JI J, Shen T, Li Y, Liu Y, et al
    CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Oncol Rep. 2021;45:921-932.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: